QFR was correlated highly with iFR as well as FFR. Like FFR and iFR, QFR might be reliable for assessing the physiological severity of coronary stenosis in the angiographic intermediate lesions.
Read more information >>
Carlos Collet and a large team of KOL co-authors under the guidance of Prof Patrick Serruys have carried out a systematic review and meta-analysis of angio-derived FFR methods, and concluded that the accuracy of angio-derived FFR was good to detect haemodynamically significant lesions with pressure-wire measured FFR as the reference. 13 studies were included of which 8 based on QFR. Click here >>
Happy to announce that our partner Pulse Medical Imaging from Shanghai, China received per 18 July, 2018 CFDA clearance for their QFR solution. For the official announcement at the CFDA website Click here >>
The team of Dr H-J Chang selected 2 matched populations of 234 patients each out of a total of 25,251 patients and found that extensive plaque burden assessment using QAngio CT identifies high-risk patients for ACS above and beyond stenosis severity and aggregate plaque burden measurement. These data suggest a potential paradigm shift wherein targeted treatment of patients and lesions possessing high-risk atherosclerotic plaque characteristics may improve therapeutic precision and outcomes.
Dr Romano and colleagues carried out a study including 1012 patients with ischemic and nonischemic dilated cardiomyopathy from 4 US centers. The patients were followed for a median period of 4.4 years. Feature-tracking based global longitudinal strain (GLS) was calculated from 3 long-axis cine-views using QStrain software application. They found from this large study that the GLS was independently associated with death in both ischemic and nonischemic dilated cardiomyopathy subgroups.
Recently, Van Herk Ventures took a minority stake in Medis medical imaging systems bv, a cardiovascular imaging software company with global market representation and a 28 years history of innovations. Medis is a technology leader in high-accuracy image analytics in cardio-vascular imaging, with solutions that are vendor independent and cover all major cardiovascular imaging modalities.
Medis raised several millions through the investment by Van Herk Ventures. The investment will be used to accelerate sales and marketing and to strengthen R&D across all product, with an emphasis on Medis’ QFR®. The terms of the investment were not disclosed.
Read complete press release >>
James P Howard and Venkatesh L Murthy wrote a beautiful Editorial Comment on the paper by Hernan Mejia-Renteria on microcirculatory dysfunction. This provides a lot of basic thoughts about coronary physiology and the different methods that are now available FFR, iFR and QFR, and this is really worth reading to understand the possibilities and limitations of these different techniques.
The team of Hernan Mejia-Renteria and Javier Escaned and other international collaborators have carried out a nice study on the influence of microcirculatory dysfunction of physiologic assessment by QFR. This is a topic of high importance and interest. The comparison was with FFR used as the reference standard. They concluded that in the group with high-IMR a significantly lower classification agreement and area-under-the-curve was found relative to the low-IMR group. But despite that, even in the presence of coronary microvascular dysfunction, QFR remains superior to angiography alone in ascertaining functional stenosis severity.
Opening ceremony on March 21 2018 in Shanghai of the joint laboratory of our partners Shanghai Jiao Tong University Medical Imaging Team with Prof Sanven Tu and Pulse medical imaging!! Congratulations!!
The team of Prof Gianluca Campo, Ferrara university in Italy, has carried out a very interesting study including 3 steps: 1) QFR reproducibility in non-culprit (NCL) coronary lesions; 2) diagnostic accuracy of QFR; and 3) long-term clinical outcomes of NCL stratified based on QFR. The reproducibility and accuracy were all excellent and consistent with other studies, and in this small cohort they concluded that QFR may be a reliable tool to guide coronary revascularization of NCL’s in ST-segment elevation MI patients.
The team of Prof Serruys has studied the impact of coronary remodeling and lumen dimensions as measured by Medis QAngioCT on fractional flow reserve FFRCT by Heartflow. They conclude that in patients with nonobstructive coronary artery disease, expansive remodeling has on impact on the CT-based FFR.
This work was carried out by the team of Prof Akasaka at Wakayama Medical University in Japan.
They analyzed fixed-flow QFR (fQFR) and contrast-flow QFR (cQFR) in 75 prior-MI-related coronary arteries and 75 non-prior-MI-related coronary arteries. The diagnostic accuracy of fQFR <_ 0.8 and cQFR<_0.8 for predicting FFR<_0.80 was found to be numerically lower in the prior-MI-related coronary arteries compared with the non-prior-MI-related coronary arteries (fQFR: 77% vs 87%; and cQFR: 87% vs 92%).
We are happy to announce that as of today QIvus® Research Edition 3.1 is available. The most important new features are:
For further information about this release please contact firstname.lastname@example.org.
Wouter M van Everdingen and his colleagues from UMCUtrecht in the Netherlands have compared strain analyses parameters in an attempt to predict which patients would benefit from Cardiac Resynchronization Therapy (CRT). They compared CMR feature tracking with Medis'QStrain, MR tagging and Echo speckle tracking in 27 CRT candidates. The conclusion of this work was that CVMR feature tracking is a potential clinical alternative for the MR tagging approach and echo speckle tracking, especially in the detection of discoordination in CRT candidates.
Researchers at NIH aimed to assess the clinical value of global and regional strain using FT-CMR in patients with ARVD/C and compared four different software packages. Despite large intersoftware variability of FT-CMR derived strain values, they found that all four packages were able to distinguish overt ARVD/C from control subjects by both global and subtricuspid strain values. The only package able to distinguish preclinical from control subjects specifically in the subtricuspid region, was QStrain. This suggests the potential to identify early ARVD/C prior to overt disease expression. Overall, the Medis QStrain solution was the most sensitive and reproducible among the four tested solutions.
This review summarizes the current state-of-the-art of invasive diagnostic methods during heart catheterization and highlights the potential role that an integration of anatomical and functional information enables.
The team of Lourens Robbers from VUMC in Amsterdam have concluded from their study that the presence of microvascular injury profoundly affects MOLLI-measured native T1 values. T2* mapping suggested that this may be the result of intramyocardial haemorrhage.
The team has carried out an in vitro validation of complex lesions in plexiglass phantoms using the QAngio CT analytical tool . They concluded that CTA is accurate for the evaluation of bifurcation lesions.
224 coronary segments were analyzed in 85 patients. Overall accuracy of contrast QFR (cQFR: no wire, no adenosine) to detect ischemia on SPECT MPI was 90%. They concluded that a good relationship between cQFR and SPECT MPI was found. QFR independently associated with ischemia on SPECT MPI and shows incremental value to detect ischemia compared to clinical and QCA parameters.
When should we use contrast material in cardiac MRI?
They analyzed 151 coronary arteries with intermediate stenosis in 142 patients. QFR had good correlation (r=0.80, P<0.0001) and agreement (mean difference: 0.01±0.05) with FFR. After applying the FFR cut-off ≤0.8, the overall accuracy rate of QFR ≤0.8 was 88.0%. On receiver operating characteristics analysis, the area under the curve was 0.93 for QFR. They concluded that QFR had good correlation and agreement with FFR and high diagnostic performance in the evaluation of intermediate coronary stenosis, suggesting that QFR may be an alternative tool for estimating myocardial ischemia.
The team of Dr Matthew Budoff concluded in a paper using Medis’ QAngio CT tool that treatment with testosterone gel for one year compared with placebo in older men with sympotomatic hypogonadism was associated with a significantly greater increase in coronary artery noncalcified plaque volume as measured by coronary computed tomographic angiography.
On Wednesday December 14, 2016 Medis received the Deshima 2016 SME Business Award for its contributions to innovations and collaborations in the field of medical imaging over a period of 15+ years at a ceremony in Tokyo. Vice-minister Maarten Camps handed over the Delft Blue Plaque.
Tu et al have published the results of the FAVOR II Pilot study and concluded as follows:
The favorable results of the contrast-flow QFR that does not require pharmacologic hyperemia induction bears the potential of a wider adoption of FFR-based lesion assessment through a reduction in procedure time, risks and costs.
From the paper: “ After six months, compared to the placebo group, those in the fish oil group had less fibrosis, or thickening and scarring, of the heart muscle in the region of the heart attack. The also had less blood left in the left ventricle of the heart after the heart muscle fully contracted, which means the heart was pumping more effectively.”
They used the T1-module of QMass and concluded that caffeine intake inverts the adenosine effect during stress perfusion CMR as measured by T1 mapping. Therefore, the ∆T1 (rest T1 minus T1 stress) can be used as a benchmark for the validity of the stress induction by adenosine at cardiac MR perfusion studies
Dr. Symons and team members compared plaque measurement reproducibility (scan-rescan) on 2 state-of-the-art CT scanners. Group (1) of 20 patients had rescan within 30 days on same scanner, while group 2 had rescan on different scanner. Plaque volumes were analyze with Medis’ QAngio CT Research Edition software. Conclusions: State-of-the-art CCTA shows excellent total, calcified and non-calcified coronary plaque reproducibility, especially with the same CT scanner. CCTA is a valid tool to reliably assess change in coronary plaque volume in both research and clinical routine.
The team from Mount Sinai Hospital, New York with last author AS Kini, MD demonstrated in a multimodality intravascular imaging study with QIvus that among a total of 383 patients ( 268 men and 115 women) with stable CAD referred for coronary angiography, that there was no difference in plaque characteristics as assessed by registered IVUS, OCT and NIRS data sets.
The new QFR for the functional assessment of coronary narrowings from 3D QCA attracted lots of attention. There were live cases from Massy (FR), Essen (DE) and Beijing (China), scientific presentations on the results of clinical trials, hands-on workshops organized by GE in their educational center, and interviews. In the following you will find pictures and the appropriate links.Early Data Hint at Good Results With Angiography-Derived FFR
Medis successfully presented the latest Medis Suite cardiac MR software at the Face-off session, EuroCMR held in Florence, Italy. The other participants in the face-off session were Circle CMR42 and Pie Medical. The task for all three participants, was to analyze 1 challenging case, and have a side-by-side comparison of the results. Medis performed very well at this face-off session by carrying out the case analysis in a truly live fashion and from scratch, by emphasizing the new automated segmentation and editing tools. We finished our presentation well within the allotted 15 minutes time slot, and even managed to show additional RV functional analysis results. The organizers commented that our results were good and accurate.
The team of Yeon Hyeon Choe, Samsung Medical Center, Seoul, S-Korea have carried out a study to determine criteria for the diagnosis of LVNC.
They measured the left ventricular trabeculated volume and the total LV myocardial volume and concluded that a trabeculated LV myocardial volume above 35% of the total myocardial volume is diagnostic for LVNC with high specificity.
EuroPCR at CIT, Session III: Live Cases III
Date: March 19, 2016
Time: 10:40 to 12:00
Location: Ballroom ABC, Level 1
They concluded from a study including 165 participants, that those with a LGE (late gadolinium enhancement) <= 35% have a favorable outcome after catheter ablation, and those with LGE >= 35% have a higher rate of AF recurrence in the first year after the ablation.
For further reading:http://imaging.onlinejacc.org
The authors conclude that in patients without history of coronary artery disease, a semi-automatically derived index of percent atheroma volume by CTA yields good accuracy for identifying obstructive coronary artery disease that is associated with myocardial perfusion abnormalities.
For further reading: http://www.journalofcardiovascularct.com/
This work was published in EuroIntervention and described their careful and stepwise approach in chronic total occlusions supported by QCA, OCT analysis, and the fusion of 3DQCA and OCT. They conclude that appropriate lesion preparation is key to aiding adequate expansion of these scaffolds in this setting.For further reading, refer to the article on http://www.pcronline.com/eurointervention/login/?url_to=/eurointervention/download_pdf.php?issue=88th&article=108&art_id=10620.
Shengxian Tu and his team have carried out an interesting study, whereby they compared two geometrical models of the same vessels, one by CTA and the other by 3D QCA. Image based FFR was computed using CFD simulations, applying the same hyperemic flow rate derived from the angio images at the inlet boundaries. They found a moderate agreement between FFRCTA and FFRQCA, and based on these observations suggest that image resolution has a significant impact on FFR computation.For further reading, refer to the article on http://link.springer.com/article/10.1007/s10554-015-0797-5?no-access=true.
The team of Kengo Tanabe, Mitsui Memorial Hospital, Tokyo demonstrated in a small study the feasibility of MSCT to assess the lumen patency and vessel disease in Absorb bioresorbable scaffolds.
The team from Ren Ji hospital, Shanghai Jiaotong university in Shanghai with first author Song Ding, MD published in Medicine very interesting results on the impact of early ST-segment changes on intramyocardial haemorrhage and microvascular obstruction as assessed by CMR.For further reading, refer to the article on http://www.ncbi.nlm.nih.gov/pubmed/26334905.
The team of U Joseph Schoepf from the Medical University of South Carolina together with investigators from 6 European sites have validated the socalled MassK threshold-based method by Medis in a total of 148 patients and concluded that “ this method may be beneficial in clinical routine to assess LV parameters in CMR studies”. The average analysis time decreased by 50% from 8.4 to 4.2 minutes, it provides improved accuracy compared to aortic flow measurements as a reference, and it has an excellent inter-observer variability.For further reading, refer to the article on http://link.springer.com/.
TT Salahuddin et al (NIH, Bethesda) have demonstrated in a study including 101 consecutive psoriasis patients that the cholesterol efflux capacity (CEC) is inversely associated with prevalent coronary plaque burden measured by quantitative coronary computed tomography angiography (QAngio CT).For further reading, refer to the article on eurheartj.oxfordjournals.org/.
The team from VU University Medical Center in Amsterdam has presented a case in the Eur Heart Journal using the Medis Mapmaker solution, which demonstrates the diagnostic potential of myocardial T1 relaxation time mapping and ECV calculation is suspected global myocardial inflammatory disease.For further reading, refer to the article on oxfordjournals.org.
The team by Yingguang Li et al have developed a fusion technique of 3D QCA and the corresponding OCT data sets, creating a true anatomical tree model including the side branches. This has effect on the results of computational fluid dynamic approaches, thus improving the consistency of biomechanical studies.For further reading, refer to the article on http://www.sciencedirect.com/science/article/pii/S0735109715022755.
3D-QCA and 3D-OCT assessment of bifurcation angles, diameter stenossis, and the area of side branch ostium(SBA). There was no change in bifurcation angle and SBA after provisional stenting.
Grundeken MJ, Ishibashi Y, Ramcharitar S, Tuinenburg JC, Reiber JHC, Tu S, Aben J-P, Girasis C, Wykrzykowska JJ, Onuma Y, Serruys PW
The need for dedicated bifurcation quantitative coronary angiography (QCA) software algorithms to evaluate bifurcation lesions.
EuroIntervention 2015; 11: V44-V49.
Tu S, Bourantas CV, Nørgaard BL, Kassab GS, Koo B-K, Reiber JHC
Image-based assessment of fractional flow reserve.
EuroIntervention 2015; 11: V50-V54.
Holm NR, Adriaenssens T, Motreff P, Shinke T, Dijkstra J, Christiansen EH
OCT for bifurcation stenting: what have we learned?
EuroIntervention 2015;11: V64-V70.
M de Graaf et al from LUMC, Leiden, The Netherlands have developed a CTA risk score based on fully automated CTA analysis using QAngio CT . The results of their study including 300 patients indicate that risk stratification in patients with CAD is feasible.Read Further on the American Journal of Cardiology.
Investigators from the University Medical Center Utrecht and the University Medical Center Groningen, the Netherlands have recently proved that the RV mass calculations are highly reproducible and superior to manual tracings in RV function parameters by CMR in a study including pressure overloaded right ventricles.For details see: Int J Cardiovasc Imaging; DOI 10.1007/s10554-014-0367-2.
A growing phenomenon in the world of medical image processing is that of “Grand challenges”. The great advantage of such challenges is that all algorithms are evaluated on the same data and using the same evaluation procedure.
This year at the MICCAI conference the Biomedical Imaging Group Rotterdam of the Erasmus MC organized a challenge on the automatic detection and quantification of stenoses in coronary CTA data (http://coronary.bigr.nl/stenoses/).The challenge contained 48 multi-center multi-vendor CTA datasets. In total 11 teams from different institutes participated in the challenge. Teams had to (semi) automatically detect and quantify coronary lesions in the CTA datasets and submit their results to an online evaluation framework. Teams where ranked according to a number of criteria in three categories: detection (ability to detect significant stenoses), quantification (comparison with observer and QCA stenoses grades) and finally lumen segmentation (compared to observer drawn contours).
At the Division of Image Processing (LKEB), Department of Radiology at the Leiden University Medical Center (LUMC), the CTA group have developed and validated robust algorithms for extraction and segmentation of coronary CTA data. This work has largely been done in within the STW CADAStr project in close collaboration with the LUMC department of cardiology and Medis medical imaging systems. These algorithms have already contributed to a number of international high ranking publications both from inside and outside the LUMC.
On the 1st of October, at the start of MICCAI 2012 conference in Nice, France a team from the LKEB/Medis (Alexander Broersen and Pieter Kitslaar), ranked 1st place in the detection and 2nd place in the quantification and segmentation categories. Based on these ranks, they were the overall winners of the on-site challenge. Congratulations, job very well done!! The algorithms are now part of the QAngio CT RE analytical software product; commercialized by Medis Specials bv (www.medisspecials.com) a Medis BV company.
Medis released on March 29, 2012 the new QAngio XA V7.3 quantification software. It has a complete new look with new icons and a tabular wizard for intuitive and fast navigation through the analysis workflow. Other very important items include:
Professor Hans Reiber has been awarded Dutch royal honours. He was presented with the royal badge and ribbon by the mayor of Leiden at a symposium of the Dutch Association for Medical Imaging at the Leiden University Medical Centre (LUMC), on October 13. Professor Reiber was unexpectedly put in the limelight when he gave his presentation as last keynote speaker of the day. He has been made an Officer in the Order of Orange-Nassau.
Hans Reiber is acknowledged worldwide as a pioneer and authority in his field: the clinical application of image analysis. Reiber also pioneered in the field of research valorization. He retired last August from the Department of Radiology at the LUMC, where he was the Head of the Laboratory for Clinical and Experimental Image Processing (LKEB). In the 1990s he established a company to make the results of his research available to clinicians. It is now a flourishing mid-sized enterprise with offices in Leiden and in Raleigh, NC, USA.
Professor Reiber has always been committed to enhancing the position of the field of Medical Imaging in the Netherlands. He is a member of the Royal Netherlands Academy of Arts and Sciences and founded the Netherlands Forum for Biomedical Imaging. Professor Bloem, Head of the Department of Radiology at the LUMC, says: “Hans Reiber has always fulfilled his role as a professor in a dedicated way, achieving more for the LUMC, for his field and for society than was strictly required”.
Medis released on Oct 16, 2011 the new QMass® MR 7.4 and QFlow® 5.4 Enterprise Solution. This new version of Cardiovascular MR post processing software has been developed for clinical day-to-day practice, where cardiologists and radiologists always find themselves pressed for time. The design enables efficient workflow as many features have been added such as a powerful MR viewer and a database for managing work. Medis’ customers with a focus on research will also appreciate the various new features and functionality that the software now encompasses.
“We learn constantly from our highly valued customers, discuss what is important for them for both clinical research and clinical practice, and set up our priority lists accordingly for the new developments. In this new Enterprise Solution, we have set a major step towards supporting the clinical users by providing a versatile cardiac MR viewer with an integrated connectivity platform. Plus we do have a new T2* analysis module in addition to all the available best-in-class quantitative analyses“, said Daniel Garcia, VP M&S of Medis medical imaging systems. "We realize that cardiac MR is increasingly used in clinical practice, and that fast and robust analyses and a thought-through workflow solution saves valuable physician and technician time.”
One of the major strong points of the Enterprise Solution is the versatile viewer, which makes it easy to compare MR data sets, offering better insights. It allows for an automatic selection of appropriate review layout for cardiac study type or disease, as well as cross-referencing and synchronization of studies, easy customization by dragging and dropping, etc.
The integrated connectivity platform allows access to cardiac MR studies across the network, built-in DICOM connectivity, including query and retrieve, and truly support for cardiac MR studies of all major MR vendors.
The QMass MR and QFlow software has been well-known for its reproducible and validated results, and that remains the backbone of the software. These include LV and RV function analysis, late-enhancement analysis, first-pass perfusion analysis of rest and stress studies, phase-contrast blood flow analysis, comparison analysis of dobutamine stress studies, and new also T2* analysis.
The powerful reporting module allows among others customizable report templates for clinical reporting, configurable normal values and z-scores, drag and drop images, automatically export results and reports to PACS.
In summary, the latest release of QMass MR Enterprise Solution now offers, a Powerful Cardiac MR viewer optimizing post-processing workflow with state of the art T2* analysis capabilities; Enterprise-wide access to cardiac datasets and cardiac clinical applications across your network, when and where you need them. Efficient Review for intelligent recognition of cardiac study type and automatic selection of the appropriate review layout enabling streamlining workflow and eliminating time-consuming tasks. Integrated Quantification allowing easy access to the best-in class QMass® MR and QFlow® software applications and fully-integrated quantification results for centralized access to reviewing, quantification and reporting.
Medis released on Sept 1, 2011 version 2.1 of its quantitative analysis software solution QIvus for intravascular ultrasound. This new version of the software has extended possibilities to review and analyze IVUS studies with tissue characterization data that visualize plaque and to also review and analyze optical coherence tomography (OCT) studies.
"We are continuously listening to our highly valued customers, and take their comments and wishes very seriously, so that we can come up regularly with new versions based on the wishes from the field. Both the clinical users, the researchers and the core lab users are very important to us. This version of QIvus 2.1 enables medical professionals to quickly analyze data acquired with all currently available intravascular imaging systems, meaning that we can process vendor-independent data sets," said Daniel Garcia, VP M&S of Medis medical imaging systems. "We are well-known for our segmentation quality and that translates into tools by which the users can analyze image runs with a minimum of effort and to get more out of the data that is already available to them."
One of the major strong points of QIvus is the extremely efficient editing capabilities of the otherwise automatically detected contours, which drastically reduces the time needed to obtain validated results from the large number of grayscale or OCT images. Analyzing IVUS or OCT image data sets becomes a matter of minutes.
This means that important data, such as plaque burden results in IVUS images can be obtained quickly and easily. In a similar way, the software provides detection of stent struts in OCT images, allowing assessment of stent malapposition and neo-intima formation.
Important new features include the IVUS-analysis of multiple stents in the same segment, the Z-offset correction in OCT image runs, and export of all analysis results to Excel, including OCT stent strut analysis and subsegment analysis, as well as improved support for Japanese and other multi-byte languages. Here again, the workflow for editing the OCT stent strut analysis has greatly improved.
For those who have data sets with tissue characterization available, QIvus 2.1 also offers the option to view and analyze the areas marked as plaque and calculate the distribution of the various plaque components. The software supports both Boston Scientific iMap™ and Volcano® VH® IVUS data sets. The iMap and VH data can be reviewed alongside the grayscale image data, and analyzed just as quickly.
All in all, the new QIvus 2.1 offers fast, accurate and reliable quantitative analysis for more types of intravascular image data sets, and builds upon the established reputation of the QIvus product.
Medis today released version 2.0 of its quantitative analysis software solution QIvus for intravascular ultrasound. The new version of the software makes it possible to review and analyze IVUS studies with tissue characterization data that visualize plaque and to also review and analyze optical coherence tomography (OCT) studies.
"This version of QIvus 2.0 enables medical professionals to quickly analyze data acquired with different intravascular imaging modalities," said Hans Reiber, President and CEO of Medis medical imaging systems. "The software gives them the tools to analyze image runs with a minimum of effort and to get more out of the data that is already available to them."
QIvus minimizes the need to edit automatically detected contours, which drastically reduces the time needed to obtain validated results from the large number of grayscale or OCT images. Analyzing IVUS or OCT image data sets becomes a matter of minutes.
This means that important data, such as plaque burden results in IVUS images can be obtained quickly and easily. In a similar way, the software provides detection of stent struts in OCT images, allowing assessment of stent malapposition and neo-intima formation.
For those who have data sets with tissue characterization available, QIvus 2.0 also offers the option to view and analyze the areas marked as plaque and calculate the distribution of the various plaque components. The software supports both Boston Scientific iMap™ and Volcano® VH® data sets. The iMap and VH data can be reviewed alongside the grayscale image data, and analyzed just as quickly.
All in all, the new QIvus 2.0 offers fast, accurate and reliable quantitative analysis for more types of intravascular image data sets.
Today, Medis released a new version of QFlow, its application for the quantification of flow and velocities in phase-contrast MR studies.
In this new version users will find, among other features, even faster contour detection and many improvements in the interface.
QFlow already featured fast, three-click contour detection for regions of interest. In QFlow 5.2, contours for up to four regions of interest can now be detected at once.
Cardiac quantification software supplier Medis today released a new version of its QMass MR software. QMass MR 7.2 makes the analysis workflow faster and offers automatic scar tissue segmentation.
QMass MR is the Medis software solution for the quantitative analysis of cardiac MR. It enables clinicians, researchers and technicians to analyze global and regional cardiac function, scar tissue and viability, and cardiac function at various stress levels.
The new version features many shortcuts and interface improvements that make working with the software faster and more intuitive. Examples are scrolling through series in the Movie Tool and one-click selection of the ED or ES phase in the Study Matrix.
For clinicians or researchers performing cardiac MR scar tissue analysis, QMass MR 7.2 provides two major improvements.
First of all, scar tissue analysis has become significantly faster because of the introduction of automatic segmentation. While the analysis can still be monitored and modified at each of the four analysis steps, the automatic segmentation reduces manual editing to a minimum.
Secondly, the scar tissue analysis in QMass MR now features double thresholding. This makes it possible to differentiate the infarct core from the peri-infarct region, and quantify those regions.
Medis medical imaging systems and MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading medical imaging software company with focus on dedicated, disease-oriented clinical applications, today announced a strategic alliance, which may lead up to a potential take-over of Medis by the MeVis Group. As a first step, MeVis has now acquired a minority stake in Medis. Terms of the transaction were not disclosed.
With its renowned products and expertise in the analysis of cardiovascular images, Medis will be a strategic addition for MeVis, expanding MeVis' portfolio of software products for the early detection, diagnosis and intervention in the areas of cancer and lung diseases as well as neurological conditions.
For Medis, the MeVis Group's successful multi-modality technology platform and its similar background in research approach (MeVis has a research relationship with the Fraunhofer Institute for Medical Image Computing MEVIS in Bremen, Germany) make MeVis the ideal partner for a strategic alliance.
The combined research experience in cardiology and radiology, and the utilization of MeVis' technology platform MeVisAP™ and its rapid prototyping platform MeVisLAB™ will ensure the rapid development of software products in the future, providing customers with the latest in both current and new software products.
"The epidemiological impact of cardiovascular disease on the global population makes the Medis products, know-how, and distribution channels a strategically significant addition to our portfolio," states Dr. Carl J.G. Evertsz, Chairman and CEO of MeVis Medical Solutions AG. "We are delighted about this strategic alliance, in which we will collaborate with the Medis team to develop and market new products for the multi-modality diagnosis of cardiovascular disease, and cardiovascular interventions."
"Our strategic partnership with MeVis means an incredibly valuable joining of forces in research, development and sales. Our customers will be able to benefit from the synergy that this partnership with the MeVis Group brings, while continuing to profit from working with familiar, high-quality products in cardiovascular quantification software", says Prof. Dr. Hans Reiber, co-founder and proprietor of Medis.
Today, Medis releases the new version of its quantitative analysis software for peripheral and coronary vessels in X-ray angiograms, QAngio XA 7.2.
This version features two major innovations in the analysis of bifurcated arteries: dedicated analysis models and edge segment analysis.
QAngio XA 7.2 gives clinicians and researchers two dedicated analysis models for bifurcations. The T-shape and Y-shape analysis models make it possible to handle differences in vessel morphology, device, and intervention strategy.
QAngio XA 7.2 also optionally features analysis results for all stent and ostial edge segments in bifurcated vessels. This allows clinicians and researchers to focus on specific segments of the vessel wall, such as stent edges, ostia of distal branches and the bifurcation core.
The QAngio XA 7.2 innovations make bifurcation analysis more flexible and enable more targeted follow-up of patients after intervention.
Started as an innovation in the Medis training program earlier this year, the e-learning sessions have proven to be a valuable educational tool. E-learning is here to stay and registration for the new season has started.
E-learning sessions consist of a 30 minute training, followed by a 10-15 minute question round. The training only requires an internet connection and a standard web browser. No additional software needs to be installed.
Currently, sessions provide a functionality overview of one of the Medis applications QAngio XA, QMass MR or QPlaque MR. Sessions focusing on new releases and specialized sessions will be scheduled in the future.
LEIDEN, the Netherlands - April 10, 2009 -- Medis, a leading provider of software for measuring in medical images, is celebrating its 20th anniversary as an innovator in quantification software. The company was founded on April 11, 1989, and has since developed into a global enterprise, with more than 4000 installations worldwide and offices in Leiden, the Netherlands and Raleigh, NC, USA.
Version 5.1 of Medis QFlow®, which was released today, provides medical specialists and technicians with an even faster and more intuitive workflow.
Among the new version's features are: faster detection of a number of regions of interest, editing innovations that make for faster and more intuitive editing, and simultaneous viewing of phase and color-coded images.
Today, Medis released version 7.1 of its cardiac MR quantification software, QMass® MR. This release features new functionality that further improves user-friendliness of the software and speeds up analysis of cardiac MR.
QMass MR 7.1 introduces automatic right ventricular contour detection, enabling fast quantification of the right ventricle.
Other features contributing to fast, reliable and easy quantification are guided workflows for volumes and scar analyses, automatic exclusion of slices that are irrelevant for volume quantification, and a range of editing innovations.
All in all, QMass MR 7.1 brings comprehensive, reliable and easy-to-use cardiac MR quantification to clinicians, while offering detailed reporting and configurability to researchers.
This year's edition of the self-assessment test, which is developed in joint collaboration by Medis and SCMR, will also be available to visitors of EuroCMR 2008, after its featuring at SCMR 2008 in Los Angeles last February.
The test enables cardiologists to assess their skills in reading cardiac MR studies. It consists of eight sets of questions, contributed by peers from the field who have selected their most interesting cases. Participants are shown their score for each set of questions that they complete.
Registration is not required for the Medis SCMR self-assessment test: it will be available to the public on a workstation next to the Medis presentation outside the EuroCMR conference hall. EuroCMR 2008 will be held in Lisbon, Portugal, from May 22 through May 24.
Medis' research partner in vessel wall imaging, the Division of Image Processing (LKEB) at the Leiden University Medical Center's Radiology Department, has been awarded the ECR 2008 first prize for Best Scientific Paper in the category "Computer Applications".
The paper, titled "Automatic detection of atherosclerotic carotid plaque from combined magnetic resonance angiography and vessel wall images", was presented by Ronald van 't Klooster, MSc. It was chosen by the ECR committee for Scientific Papers because of its scientific content, the quality of the images, and the quality of the presentation.
Today, Medis released version 1.1 of its software solution for the analysis of stenoses in CTA studies, QAngio CT.
The new version features improvements based on customer feedback. Enhancements include improved segmentation and detection, improved performance, more versatile viewing, and additional reporting.
The 2008 edition of the European Congress of Radiology's IMAGINE exhibit will feature a presentation of current research projects at Medis and its research partner LKEB (Division of Image Processing, Leiden University Medical Center).
The ECR high-tech specialty exhibit highlights the latest technological developments from ten European research institutes, university groups and research departments of industrial companies. It gives radiologists the opportunity to see and discuss the potential of new techniques.
Medis and LKEB will present ongoing research in two areas of interest: the quantification of brain MRI and the quantification of the vessel wall in multi-spectral MR studies of carotid arteries.
The US Food and Drug Administration (FDA) has provided market clearance for QPlaque MR, Medis' software solution for the analysis of the vessel wall in multi-spectral MR studies of the carotid arteries.
This clearance of Medis' latest solution for vascular analysis means that clinicians and researchers can now obtain reliable quantitative data to support the assessment of vessel wall condition in patients with atherosclerosis.
Come see us at one of the following congresses and discover how Medis software products can help you make post-processing more accessible and more efficient.
|EuroEcho||Milan, Italy||5 – 8 december|